AtriCure
Logotype for AtriCure Inc

AtriCure (ATRC) investor relations material

AtriCure Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for AtriCure Inc
Stifel 2026 Healthcare Conference 2026 summary11 Nov, 2026

Outlook and investment

  • 2026 revenue guidance set at $606M-$610M; the lower implied Q4 growth rate reflects prudent conservatism, with international and U.S. hybrid business cited as potential headwinds.

  • The 2028 long-range plan targets $750M revenue and 14% adjusted EBITDA margin; management cited continued mid-teens revenue growth and catalysts that could support further outperformance.

  • Manufacturing expansion will effectively double production capability; facility costs may weigh on near-term gross margin before capacity is fully utilized, while newer products support high margins.

  • Investment is increasing in R&D and new product development while profitability progress continues; transformational M&A is not a current focus.

Quality metric and BoxX

  • STS quality metric rollout starts with a 70% goal and is expected to rise toward 90%+ over time; 2027 is expected to focus on awareness and reporting, with twice-yearly harvest periods.

  • STS will assess sites, with results also broken down by surgeon; the metric is expected to promote both appendage management and ablation, as the combined procedures provide benefits.

  • BoxX targets post-op AFib, which management cited at 35%-55% in controlled settings; trial endpoints assess 30-day post-op AFib and AFib burden over three years.

  • BoxX enrollment is expected to finish by year-end 2026; the 30-day endpoint is planned for May 2027, while the three-year endpoint will take longer to mature.

  • A 10 percentage-point absolute reduction in post-op AFib is considered clinically relevant; BoxX may have greater 2027 potential than the quality metric, though aggressive marketing awaits FDA labeling.

Products and clinical pipeline

  • A 30 mm FLEX-Mini clip is expected to launch in late 2026 after FDA clearance; FLEX-Mini V is in development, with clearance and launch expected in late 2027.

  • Edwards’ ECLIPTIS device is being introduced in the field, but management reported little headwind to date and emphasized its product, evidence base and experienced field team.

  • LEAPS enrolled in July 2025 and has reached 50% of its 469 events; the 75% event milestone is anticipated in 2028, potentially before the original five-year expectation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next AtriCure earnings date

Logotype for AtriCure Inc
Q4 202612 Feb, 2027
AtriCure
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next AtriCure earnings date

Logotype for AtriCure Inc
Q4 202612 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

AtriCure Inc develops and sells medical devices for the surgical treatment of atrial fibrillation and related conditions. The company offers ablation systems, surgical instruments, and cryoablation technologies used in both open-heart and minimally invasive procedures. The company is headquartered in Mason, Ohio, and its shares are listed on the NASDAQ.